CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (47,809,000)	$ (116,168,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17,946,000	15,118,000
Non-cash interest expense	1,285,000	1,134,000
Amortization (accretion) of discounts/premiums on investments, net	530,000	(779,000)
Amortization of debt discount and issuance costs	7,789,000	7,397,000
Provision for Inventory	1,317,000	972,000
Share-based compensation	16,612,000	16,101,000
ESPP expense	650,000	507,000
Change in fair value of contingent consideration	7,448,000	(12,180,000)
Payments related to change in fair value of contingent consideration	(10,268,000)	(4,329,000)
Write off of IPR&D intangible assets	0	25,500,000
Impairment of long-term investment	0	15,000,000
Unrealized foreign currency transaction gain (loss)	117,000	539,000
Other	446,000	15,000
Changes in operating assets and liabilities:
Accounts receivable	3,195,000	(3,989,000)
Inventory	(3,813,000)	(671,000)
Tax receivable	(12,220,000)	0
Other current and non-current operating assets	(20,181,000)	(9,629,000)
Accounts payable and accrued expenses	(10,213,000)	4,962,000
Other current and non-current operating liabilities	18,296,000	6,778,000
Net cash used in operating activities	(28,873,000)	(53,722,000)
Cash Flows From Investing Activities:
Purchase of fixed assets	(2,926,000)	(286,000)
Cash paid for intangible assets	(13,039,000)	(11,299,000)
Proceeds from the sale/maturity of debt securities	223,152,000	180,818,000
Purchase of debt securities	(143,003,000)	(150,950,000)
Net cash provided by investing activities	64,184,000	18,283,000
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	(6,886,000)	(2,562,000)
Payment of guaranteed minimum royalty	(1,575,000)	(1,559,000)
Proceeds from exercise of stock options	1,345,000	944,000
Proceeds from issuance of common stock, net of issuance costs	108,692,000	0
Proceeds from issuances under employee stock purchase plan	1,098,000	1,005,000
Net cash provided by (used in) financing activities	102,674,000	(2,172,000)
Effect of exchange rate changes on cash	60,000	(74,000)
Net change in cash and cash equivalents	138,045,000	(37,685,000)
Cash and cash equivalents, beginning of year	62,436,000	102,873,000
Cash and cash equivalents, end of period	$ 200,481,000	$ 65,188,000